What is Tesamorelin 10mg + Ipamorelin 10mg Blend?
This enhanced-ratio blend combines Tesamorelin (GHRH analogue, 10mg/vial) and Ipamorelin (selective GHRp/ghrelin mimetic, 10mg/vial) in an equal 1:1 ratio. Tesamorelin triggers GH pulse amplitude via the GHRH receptor; Ipamorelin amplifies GH pulse frequency via GHS-R1a without significantly elevating cortisol or prolactin. Together they act synergistically on the pituitary for additive GH release. The 20mg/vial format (vs 17mg previous) allows precise equal-dose research of both components simultaneously. Research use only.
Research Applications
Equal-Ratio GHRH + GHRp Synergy
Pituitary co-stimulation at 1:1 Tesamorelin:Ipamorelin ratio — GH pulse amplitude + frequency
GH Axis & Pituitary Research
GHRH-R and GHS-R1a simultaneous activation, somatostatin suppression, GH secretion dynamics
IGF-1 Upregulation
Hepatic IGF-1 production, somatomedin signalling, tissue anabolic response
Body Composition Research
Visceral adipose reduction, lean mass, lipodystrophy models
Dose-Response vs 17mg Blend
Comparative studies: 20mg equal-ratio vs 17mg (11+6) asymmetric blend — receptor contribution
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 218949-48-9 / 170851-70-4 |
| Molecular Formula | Tesamorelin C₂₂₁H₃₆N₇₂O₇S + Ipamorelin C₃₈H₄₉N₉O₅ |
| Peptide Type | GHRH + GHRp Dual-Action Blend (20mg/vial) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | −20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months (unopened) |

